.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Accenture
Novartis
UBS
Chinese Patent Office
US Army
Healthtrust
Federal Trade Commission
Daiichi Sankyo
Mallinckrodt

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Plasticizers for coating compositions
Abstract: A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Inventor(s): Pacetti; Stephen Dirk (San Jose, CA), Tang; Yiwen (Sunnyvale, CA), Hossainy; Syed Faiyaz Ahmed (Hayward, CA)
Assignee: Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Application Number:14/621,301
Patent Claims:1. A polymeric coating for an implantable device, the coating comprising a biocompatible polymer and a biocompatible plasticizer, the plasticizer being in the range between 0.1% and 40% by weight of the coating; wherein the plasticizer is a linear oligomer of a monomer selected from the group consisting of glycolic acid, L-lactic acid, D-lactic acid, D, L-lactic acid, 3-hydroxypropanoic acid, 3-hydroxybutyric acid, 4-hydroxybutyric acid, 3-hydroxyvalerate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 5-hydroxyhexanoate, .epsilon.-caprolactone, 6-hydroxycaproic acid, .gamma.-butyrolactone, .beta.-butyrolactone and combinations thereof; and wherein the linear oligomer is a dimer, a trimer, a tetramer, or a combination thereof.

2. The polymeric coating of claim 1, wherein the biocompatible polymer is bioabsorbable, biodegradable or non-absorbable.

3. The polymeric coating of claim 1, wherein the biocompatible polymer is selected from the group consisting of poly(L-lactide), poly(D-lactide), poly(D,L-lactide), poly(D,L-lactide-co-L-lactide), poly(D,L-lactide-co-glycolide) (PDLLAGA), poly(L-lactide-co-glycolide), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), ethylene vinyl alcohol copolymer (EVOH), poly(glycolic acid-co-trimethylene carbonate), polyvinylidene chloride, polyacrylonitrile, Nylon 66, polycaprolactam, polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), polyacrylamide (PAAm), poly(glyceryl sebacate), poly(propylene fumarate), rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, carboxymethyl cellulose, and combinations thereof.

4. The polymeric coating of claim 1, further comprising a biobeneficial material.

5. The polymeric coating of claim 4, wherein the biobeneficial material is selected from the group consisting of block copolymers of poly(ethylene glycol terephthalate)/poly(butylene terephthalate) (PEGT/PBT), poly(ethylene oxide-co-D,L-lactic acid) (PEO/PDLLA), poly(ethylene oxide), poly(propylene oxide), phosphoryl choline, choline, poly(aspirin), SIS-PEG, polystyrene-polyethylene glycol (polystyrene-PEG), polyisobutylene-PEG, PCL-PEG, PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), poly(dimethyl-siloxane)-PEG (PDMS-PEG), poloxamer surfactants, poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments of hyaluronic acid, heparin, fragments of heparin, glycosaminoglycans (GAG), polysaccharides, elastin, chitosan, alginate, and combinations thereof.

6. The polymeric coating of claim 1, further comprising a bioactive agent.

7. The polymeric coating of claim 6, wherein the bioactive agent is selected from the group consisting of steroids, anticancer agents, nucleic acids, peptides, proteins, antibodies, antibiotics, anesthetics, vaccines, anti-inflammatory drugs, anti-coagulant agents, antisense oligonucleotides, and combinations thereof.

8. The polymeric coating of claim 6, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), pimecrolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, zotarolimus, clobetasol, bioactive RGD, CD-34 antibody, abciximab, progenitor cell capturing antibody, and combinations thereof.

9. The polymeric coating of claim 1, further comprising an oligomer of poly(D,L-lactic acid) (PDLLA) of a molecular weight in the range from 1000 Daltons to 5,000 Daltons.

10. The polymeric coating of claim 1, wherein the biocompatible polymer is selected from the group consisting of poly(ester amide)s, poly(hydroxyvalerate), polycaprolactone, polydioxanone, polyorthoesters, polyanhydrides, polyphosphoesters, polyphosphoester urethanes, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonates), polyurethanes, polyphosphazenes, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, polyvinyl chloride, polyvinyl ethers, polyvinyl methyl ether, polyvinylidene halides, polyvinyl ketones, polyvinyl aromatics, polyvinyl esters, copolymers of vinyl monomers with each other and olefins, ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, ethylene-vinyl acetate copolymers, polyamides, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, cellulose ethers, and combinations thereof.

11. The polymeric coating of claim 4, wherein the biobeneficial material is selected from the group consisting of poly(ether ester)s, polyalkylene oxalates, polyalkylene oxides, polyphosphazenes, polymers and co-polymers of hydroxyl bearing monomers, hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, alkoxymethacrylates, alkoxyacrylates, PEG acrylates (PEGA), PEG methacrylates, 2-methacryloyloxyethyl-phosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), polymers and co-polymers of carboxylic acid bearing monomers, methacrylic acid (MA), acrylic acid (AA), and 3-trimethylsilylpropyl methacrylate (TMSPMA), biomolecules, silicones, and combinations thereof.

12. The polymeric coating of claim 4, wherein the biobeneficial material is selected from the group consisting of block copolymers of poly(ethylene glycol terephthalate)/poly(butylene terephthalate) (PEGT/PBT), poly(ether ester)s, polyalkylene oxalates, poly(ethylene oxide-co-D,L-lactic acid) (PEO/PDLLA), polyalkylene oxides, poly(ethylene oxide), poly(propylene oxide), polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers, hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, alkoxymethacrylate, alkoxyacrylate, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), polymers and co-polymers of carboxylic acid bearing monomers, methacrylic acid (MA), acrylic acid (AA), and 3-trimethylsilylpropyl methacrylate (TMSPMA), SIS-PEG, polystyrene-PEG, polyisobutylene-PEG, PCL-PEG, PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), poly(dimethylsiloxane)-PEG (PDMS-PEG), PVDF-PEG, polypropylene oxide-co-polyethylene glycol surfactants, poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments of hyaluronic acid, heparin, fragments of heparin, glycosamino glycan (GAG), polysaccharide, elastin, chitosan, alginate, silicones, and combinations thereof.

13. A method of treating a human being in need of treatment of a disorder comprising implanting in the human being a medical device comprising the polymeric coating of claim 1, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

14. A method of treating a human being in need of treatment of a disorder comprising implanting in the human being a medical device comprising the polymeric coating of claim 6, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

15. A method of treating a human being in need of treatment of a disorder comprising implanting in the human being a medical device comprising the polymeric coating of claim 7, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

16. A method of treating a human being in need of treatment of a disorder comprising implanting in the human being a medical device comprising the polymeric coating of claim 8, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

17. An implantable device comprising the polymeric coating of claim 1.

18. An implantable device comprising the polymeric coating of claim 6.

19. An implantable device comprising the polymeric coating of claim 7.

20. An implantable device comprising the polymeric coating of claim 8.

21. The polymeric coating of claim 1, wherein the plasticizer is in the range of 1% to 20% by weight of the coating.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Centocor Inc
REOPRO
abciximab
INJECTABLE; INJECTION1035750011994-12-22► Subscribe Abbott Cardiovascular Systems Inc. (Santa Clara, CA) Pacetti; Stephen Dirk (San Jose, CA), Tang; Yiwen (Sunnyvale, CA), Hossainy; Syed Faiyaz Ahmed (Hayward, CA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
United States of America2009238854Sep 24, 2009
United States of America2015150989Jun 04, 2015
United States of America8980300Mar 17, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Colorcon
Citi
Chinese Patent Office
Cipla
Cerilliant
Johnson and Johnson
Cantor Fitzgerald
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot